Fig. 2From: Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinationsKaplan Meier curve estimating OS for 55 patients from the next line of systemic therapy for kidney cancer after discontinuation of IO-VEGF. Median OS was 24.5āmonths (95% CI, 12.0ā NE) and 12-month OS probability was 63.3% (95% CI, 48.6ā74.9). Median follow up time for survivors was 18āmonths (range: 0, 44). OS (Overal Survival), IO-VEGF (Immune-Oncology and Vascular Endothelial Growth Factor targeted therapy)Back to article page